arrow_back
  • GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. KITE and the KITE logo are trademarks of Kite Pharma, Inc. © 2024 Gilead Sciences, Inc. All rights reserved. IHQ-UNB-5423 March 2024

Cell therapy clinical program.

We are commited to patients living with blood cancer.
Explore ongoing trials, enrolling trials, and MoAs our trials are investigating.

Our pipeline.

Our pipeline includes various targets and approaches in oncology today, from antibody-drug conjugates and small molecules to cell therapy-based approaches.

The result of this approach is a portfolio that includes many assets with complementary mechanisms of action and strong potential to span diverse tumor types and lines of therapy, both on their own and in combinations.

Breast clinical program.

We are commited to patients living with breast cancer.
Explore ongoing trials, enrolling trials, and MoAs our trials are investigating.

Thoracic clinical program.

We are commited to patients living with Thoracic cancer.
Explore ongoing trials, enrolling trials, and MoAs our trials are investigating.

GU/GI/GYN clinical program.

We are commited to patients living with GU/GI/GYN cancer.
Explore ongoing trials, enrolling trials, and MoAs our trials are investigating.

keyboard_arrow_up
keyboard_arrow_down